#ESMO26 🇪🇸 Top Lung Abstracts 🫁

#SAFFRON Phase 3 study of #savolitinib + osimertinib vs. platinum–pemetrexed for MET- driven resistance post osimertinib (N=338)

🎯 MET IHC 3+/ Amp (FISH)>10
🎯 PFS: 7.6 vs 5.4 mo (HR 0.55)
🎯 OS: 17.8 vs 12.9 mo (HR 0.68)
🎯 ORR: 51% vs 27%

⚠️ AEs: Edema & GI toxicity
👉🏽 Clinical Challenge - Although MET resistance post osi can occur 20-30%, it is hard to test for this prospectively in clinic- requires repeat biopsy🔪

#LCSM #LungCancer @EGFRResisters